2022
Occupational and environmental exposures in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study
Ryan SM, Mroz MM, Herzog EL, Ryu C, Fingerlin TE, Maier LA, Gulati M. Occupational and environmental exposures in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study. Respiratory Medicine 2022, 200: 106923. PMID: 35932543, DOI: 10.1016/j.rmed.2022.106923.Peer-Reviewed Original ResearchConceptsAlpha-1 antitrypsin deficiencyCardiac sarcoidosisSarcoidosis StudyAntitrypsin deficiencyRadiation exposureNon-cardiac sarcoidosisNon-chronic diseasesMultiple comparisonsEnvironmental exposure dataExtrapulmonary diseasePulmonary involvementGranulomatous disorderSarcoidosis phenotypesRisk factorsSpecific disease phenotypesStage 0Number of exposuresSarcoidosisExposure assessment toolsSusceptible individualsSpecific exposuresDiseaseEnvironmental exposuresExposure dataIndividual exposureInhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications 2022, 13: 3140. PMID: 35668129, PMCID: PMC9170782, DOI: 10.1038/s41467-022-30615-x.Peer-Reviewed Original ResearchConceptsType 1 immunityInternal organ involvementOrgan involvementT cell-derived IFNIdiopathic inflammatory disorderOpen-label trialMonths of treatmentType 1 cytokinesJanus kinase inhibitorImmunologic changesLongstanding sarcoidosisSarcoidosis activitySarcoidosis symptomsClinical improvementCutaneous sarcoidosisSecondary outcomesComplete responsePrimary outcomeTofacitinib treatmentActivity scoreCytokine mediatorsIL-12IL-15IL-6Inflammatory disorders
2021
Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis
Vukmirovic M, Yan X, Gibson KF, Gulati M, Schupp JC, DeIuliis G, Adams TS, Hu B, Mihaljinec A, Woolard TN, Lynn H, Emeagwali N, Herzog EL, Chen ES, Morris A, Leader JK, Zhang Y, Garcia JGN, Maier LA, Collman RG, Drake WP, Becich MJ, Hochheiser H, Wisniewski SR, Benos PV, Moller DR, Prasse A, Koth LL, Kaminski N. Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis. European Respiratory Journal 2021, 58: 2002950. PMID: 34083402, PMCID: PMC9759791, DOI: 10.1183/13993003.02950-2020.Peer-Reviewed Original ResearchMeSH KeywordsBronchoalveolar LavageBronchoalveolar Lavage FluidHumansSarcoidosisSarcoidosis, PulmonaryTranscriptomeConceptsWeighted gene co-expression network analysisGene co-expression network analysisCo-expression network analysisGene expression programsGene expression patternsDistinct transcriptional programsImmune response pathwaysIon Torrent ProtonMicroarray expression datasetsExpression programsTranscriptional programsPhenotypic traitsGene modulesResponse pathwaysRNA sequencingMolecular endotypesExpression patternsGene expressionHilar lymphadenopathyOrgan involvementGenomic researchMechanistic targetExpression datasetsT helper type 1T cell immune responsesElevated IL-15 concentrations in the sarcoidosis lung are independent of granuloma burden and disease phenotypes
Minasyan M, Sharma L, Pivarnik T, Liu W, Adams T, Bermejo S, Peng X, Liu A, Ishikawa G, Perry C, Kaminski N, Gulati M, Herzog EL, Dela Cruz CS, Ryu C. Elevated IL-15 concentrations in the sarcoidosis lung are independent of granuloma burden and disease phenotypes. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2021, 320: l1137-l1146. PMID: 33851886, PMCID: PMC8285626, DOI: 10.1152/ajplung.00575.2020.Peer-Reviewed Original ResearchConceptsIL-15 concentrationsIL-15Bronchoalveolar lavageDisease pathogenesisSarcoidosis lungClinical manifestationsLineages of miceIL-15 receptor αHuman cohortsInflammation of sarcoidosisIL-15 levelsOngoing inflammatory processSystemic granulomatous diseaseNumber of granulomasDisease phenotypeSarcoidosis cohortTDM administrationGranuloma numberComorbid conditionsClinical progressionInterleukin-15Granulomatous diseaseInflammatory processGranuloma formationHealthy controls
2017
Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report
Ryu C, Herzog EL, Pan H, Homer R, Gulati M. Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report. American Journal Of Case Reports 2017, 18: 157-159. PMID: 28190872, PMCID: PMC5319306, DOI: 10.12659/ajcr.902231.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsUpper airway obstructionRare extrapulmonary manifestationLaryngeal sarcoidosisLife-threatening complicationsAirway obstructionEmergent tracheostomyExtrapulmonary manifestationsCase reportComplete upper airway obstructionLow-dose prednisoneMonths of corticosteroidsStage 1 sarcoidosisAddition of methotrexateAfrican American femalesTapered dosageRespiratory failureSevere dyspneaInspiratory stridorSignificant morbidityPhysical examinationChronic careAryepiglottic foldsTimely diagnosisSarcoidosisPrednisone
2000
Impatient Inpatient Care
Gulati M, Saint S, Tierney L. Impatient Inpatient Care. New England Journal Of Medicine 2000, 342: 37-40. PMID: 10620648, DOI: 10.1056/nejm200001063420107.Peer-Reviewed Original Research